SCHEMBL5751013

SCHEMBL5751013

O=C(Nc1ccc(F)c(Cl)c1)Nc1nc2ccncc2cc1-c1ccsc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
LMNA P02545 4/20 0.53
HTT P42858 3/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 4/20 0.51
IDH2 P48735 2/20 0.49
TDP2 O95551 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
SLC2A1 P11166 1/20 0.44
CNR1 P21554 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CSNK2A1 P68400 2/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5750679 0.88 KMT2A (0.45) KMT2AMEN1HTTTP53MAPT
SCHEMBL5750761 0.87 MEN1 (0.55) KMT2AMEN1LMNAHTTTP53
SCHEMBL5747783 0.85 MEN1 (0.53) KMT2AMEN1LMNAHTTTP53
SCHEMBL5750210 0.83 KMT2A (0.52) KMT2AMEN1LMNAHTTTP53
SCHEMBL5749672 0.81 MEN1 (0.54) KMT2AMEN1LMNAHTTTP53
SCHEMBL5749819 0.80 ALDH1A1 (0.54) KMT2AMEN1LMNAHTTMAPT
SCHEMBL5750784 0.80 FGFR1 (0.43) CSNK2A2CSNK2B
SCHEMBL5751137 0.80 MEN1 (0.52) KMT2AMEN1LMNAHTTTP53
SCHEMBL5866960 0.79 KMT2A (0.48) KMT2AMEN1LMNAHTTTP53
SCHEMBL5749766 0.78 MEN1 (0.51) KMT2AMEN1LMNAHTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1372648-B1 TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES SMITHKLINE BEECHAM CORP (US) 2006-03-15 EP disclosed
US-7005434-B2 Compounds and uses thereof SB CORPORATION (US) 2006-02-28 US disclosed
US-20040048888-A1 Novel compounds and uses thereof SMITHKLINE BEECHAM CORPORATION 2004-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048888-A1 Novel compounds and uses thereof TEK, TIE1, KDR KMT2A 1785/4885MEN1 1650/4885LMNA 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.